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Objective. Familial Mediterranean fever (FMF) is an autoinflammatory disease manifested as recurrent serosal inflammation. An association between FMF and malignancy has not been evaluated. The aim of this study was to estimate cancer risk in a large cohort of FMF patients from a single institution.
Methods. The study cohort consisted of 8,534 FMF patients registered at the National FMF Center in Tel Hashomer, Israel. We linked the study cohort to the database of the Israel National Cancer Registry using the national identity number. Cancer incidence in FMF patients was determined and then stratified by age and sex. Standardized incidence ratios (SIRs) for cancers were calculated.
Results. Among 8,534 FMF patients (4,400 men, 4,134 women), 350 developed cancer during the years 1970-2011. The overall cancer risk among patients with FMF was significantly lower than was expected in specific sex and ethnic groups of the Israeli population: for males of Jewish ethnicity, SIR 0.66 (95% confidence interval [95% CI] 0.55-0.77), P < 0.001; for females of Jewish ethnicity, SIR 0.75 (95% CI 0.64-0.86), P < 0.001; and for males of Arab ethnicity, SIR 0.34 (95% CI 0.07-0.99), P = 0.024.
Conclusion. FMF patients have a significantly lower incidence of cancer than the general population of Israel. This pattern was demonstrated in 2 ethnic populations: Jewish and Arab. We speculate that the lower cancer incidence could be attributed to a direct physiologic effect of FMF or to its treatment.
Familial Mediterranean fever (FMF) is a hereditary autoinflammatory disease characterized by recurrent self-limiting attacks of fever and serositis. Renal amyloidosis culminating in renal failure, which occurs in as many as 60% of untreated patients with FMF, is the major cause of death in FMF (1, 2) . The disease occurs primarily in Mediterranean populations, such as Sephardic Jews, Armenians, Turks, Arabs, and Druze, but is also found in various proportions in other populations (1, 3) . The mode of inheritance is autosomal recessive, with mutations in the Mediterranean fever gene MEFV (4). MEFV encodes for the pyrin protein (5), which is a key regulator of the inflammasome, a major mediator of the innate immune system. This cytoplasmic protein is expressed mainly in circulating myeloid lineage cells, synovial fibroblasts, and dendritic cells (6) but has also been found in cell lines derived from colorectal and prostate cancer (7) . Due to the low sensitivity and specificity of genetic tests, the diagnosis of FMF is based mainly on the clinical presentation and response to treatment with colchicine.
Autoimmune inflammatory conditions, including systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), systemic sclerosis, and Sj€ ogren's syndrome, have been associated with a higher incidence of cancer (8) . These autoimmune conditions mainly develop as a result of dysfunction of the adaptive immune system (9), which through various mechanisms, leads to a propensity for cancer (10) . FMF is a member of a group of inflammatory syndromes referred to as autoinflammatory diseases. Autoinflammatory diseases are thought to derive from dysfunction of the innate immune system (9) . To date, an association of FMF, as well as any of the other autoinflammatory diseases, with cancer incidence has not been studied.
The established linkage between autoimmunerelated inflammatory conditions and malignancy prompted us to evaluate the association between FMF and cancer. We hypothesized that, similar to other immune-related diseases, the burden of inflammation may predispose FMF patients to the development of cancer. This may particularly affect serosal membranes (peritoneum, pleura, and joints), which in FMF patients, are recurrently exposed to inflammation, thereby leading to the development of malignancies, such as mesotheliomas and joint sarcomas, or the inflammation may involve organs that are active in the immune response, thereby leading to the development of lymphomas. In this study, we evaluated the incidence of cancer in a large cohort of FMF patients and compared the risk of cancer in this cohort to that in the general population of Israel.
PATIENTS AND METHODS
Study design. We conducted a retrospective study of FMF patients registered at the National Center for FMF at Tel Hashomer Hospital. Data regarding cancer in the FMF cohort were obtained from the Israel National Cancer Registry (INCR). We compared cancer incidence in our FMF cohort to that in the general population of Israel, with adjustment for age, sex, and ethnicity.
Patient selection. Data were accessed from the National Center for FMF at the Heller Institute of Medical Research, Sheba Medical Center in Tel Hashomer. This center, the main facility for the diagnosis and treatment of FMF patients in Israel, serves patients referred by primary care physicians and specialists from around the country. At the time the study was conducted, the registry consisted of~8,500 patients; most were being monitored annually or more frequently if required. Most of the patients were diagnosed at our center, usually at the first appointment, based on information from their medical history, their letter of referral, and other documents. The diagnosis was entirely clinical. Mutation analysis of the MEFV gene served only as an ancillary tool. This study included consecutive patients diagnosed as having FMF from 1979 to 2008.
Ethnic classification. Due to observed differences in cancer incidence in Israel according to ethnic origin, we classified patients by ethnic origin, based on their own and their parents' places of birth. Patients were stratified by sex and by ethnic group (Jewish, Arab, or undetermined), and the Jewish population was substratified as Ashkenazi (derived from European countries) and Sephardic (originating from Middle Eastern countries, North Africa, and Western Asia). This further stratification was done because in addition to differences in cancer incidence between Ashkenazi and Sephardic Jews, FMF in Jews is mainly a disease of Sephardic Jews.
Cancer diagnosis according to the INCR. The list of FMF patients was linked by individual national identity numbers to records in the database of the INCR. The INCR was established in 1960, and mandatory reporting to the registry began in 1982. We extracted data regarding cancer from the establishment of the INCR until 2011. The completeness of the INCR is~94% for solid tumors (11) . The INCR records all clinical and demographic data for Israeli patients diagnosed as having cancer (with the exception of non-melanoma skin cancers), as well as benign tumors of the brain and central nervous system. The site of cancer and its morphology are coded according to the International Classification of Diseases for Oncology, Third Edition (ICD-O-3) (12) . Vital status of the registry subjects and date of death, where applicable, are updated annually in the registry through linkage with mortality data provided by the Israel Bureau of Statistics. The name, date of birth, and sex of each patient were used to verify matches to the cancer registry database.
Statistical analysis. Cancer incidence in the FMF cohort was compared to that of the general population using indirect age adjustment. In indirect adjustment, a standardized incidence ratio (SIR) is calculated as the observed number of cancer cases occurring in the cohort over the course of the observation period divided by the number of cases expected to occur if the age-specific rates in the general population were applied to the age distribution of person-years of follow-up time. Follow-up time for each person in the study cohort was calculated as the number of years contributed by that person from the date of birth until the first of the following: 1) date of cancer diagnosis, 2) date of death, or 3) end of the observation period. The expected number of diagnoses was calculated by applying age-specific rates in the general population (for a specific sex and ethnic group) to the total number of person-years in each age group contributed by the cohort in the same sex and ethnic group. We calculated cancer incidence, overall and by subpopulation and sex group, as the number of observed cases divided by the number of personyears of follow-up for the relevant group. Due to the genetic nature of FMF, we calculated person-years of disease exposure for each patient from the date of birth. For each population and sex subgroup in the FMF cohort, we calculated the expected number of cancer cases using age-, sex-, subpopulation-, and calendar period-specific incidence rates for the Israeli population. The mean age at the end of the follow-up period was calculated for the various ethnic groups. Age-and sex-specific cancer incidence figures are not available for the Sephardic and Ashkenazi Jewish populations. We therefore used cancer rates for Jewish Israelis born in Asia or Africa to calculate the expected number of cases in the Sephardic subgroup of FMF patients and cancer rates for Jewish Israelis born in Europe or America to calculate the expected number of cases in the Ashkenazi subgroup. Exact 95% confidence intervals (95% CIs) calculated from binomial distributions were calculated for the SIRs.
RESULTS
The study cohort consisted of 8,534 FMF patients, 4,400 (51.6%) males and 4,134 (48.4%) females, with a total of 258,803 person-years of follow-up. The mean AE SD age at the time of our study was 43.74 AE 14.7 years. Table 1 shows the distribution of the study cohort according to ethnicity and sex. Of all the FMF patients, 85.2% were of Jewish origin, 6.5% were of Arab or Druze origin, and 8.3% were of unknown ethnicity. Sephardic Jews were the majority (76.9%). A total of 41% of the patients were Sephardic Jews of African origin, 24% were of Asian, and 12.3% of mixed African/Asian origin. The Ashkenazi Jews were a small minority (2%), and 6.2% of them were of mixed Ashkenazi/Sephardic origin.
Of the 8,534 FMF patients, 350 (4.1%) were diagnosed as having cancer: 205 were female and 145 were male. The mean AE SD age at cancer diagnosis was 52.6 AE 15.8 years (55.8 years for men and 50.4 years for women). Table 2 shows the rates of all cancer cases according to ethnicity and sex. Table 3 provides the distribution of the specific cancer types. Among females, breast cancer was the most frequent cancer diagnosed (24%), followed by cervical cancer (16%) and lymphoma (6.3%). In men, colorectal cancer (16.6%) was most common, followed by prostate cancer (14.5%), and lung cancer (12%).
Significantly lower rates of cancer were found in Jewish males and females with FMF (in males, SIR 0.66 [95% CI 0.55-0.77], P < 0.001; in females, SIR 0.75 [95% CI 0.64-0.86], P < 0.001), as well as in Arab males with FMF (SIR 0.34 [95% CI 0.07-0.99], P = 0.024) than was expected from the national cancer incidence rates for each of these population groups (Table 4) .
Analysis of specific cancer types in Sephardic Jewish men revealed a significantly lower incidence of gastrointestinal non-colorectal cancers than was expected (SIR 0.07 [95% CI 0.00-0.04], P < 0.001) ( Table 4) . Sephardic Jewish female FMF patients had a lower incidence of breast cancer than was expected (SIR 0.72 [95% CI 0.50-0.99], P = 0.023) ( Table 5) . A higher than expected rate of cervical cancer (SIR 1.84 [95% CI 1.18-2.74], P = 0.004) was found in Sephardic women (Table 5 ). This was attributed to a higher incidence of in situ cervical cancer. Furthermore, an excess risk of multiple myeloma was observed among Sephardic males (SIR 3.83 [95% CI 1.65-7.54], P = 0.002).
DISCUSSION
In this study of a large cohort of patients with FMF, we found a lower incidence of cancer in Jewish patients of both sexes and in Arab male patients as compared to the national registry data for the corresponding population. When stratifying our findings according to cancer type, noncolorectal gastrointestinal cancer and breast cancer were significantly reduced in the Saphardic Jewish population.
This study is the first to show a negative correlation between an autoinflammatory disease and cancer incidence, and it is in complete contrast to our expectation, as presented above. However, most epidemiologic studies that have demonstrated an increased cancer incidence in patients with chronic inflammatory (17, 18) . These autoimmune diseases are due to dysfunction of the adaptive immune system, originating from errors in self-nonself discrimination and involving autoreactive T and B lymphocytes (19) . In addition, autoimmune diseases are associated with specific alleles of the major histocompatibility complex (MHC) that encode proteins involved in antigen presentation of peptides to T cells (20, 21) and are characterized by a predominance of females. In contrast, FMF, along with other autoinflammatory diseases, results from dysfunction of the innate immune system, specifically the inflammasome and the interleukin-1 pathways (22, 23) . Thus, autoinflammatory diseases arise from inappropriate activation of inflammatory mechanisms that are unrelated to antigen specificity (1, 2) . Patients with autoinflammatory diseases lack autoantibodies and MHC associations, and there is no female predominance (24, 25) . In a study of 75,000 patients with rheumatologic conditions such as SLE, Sj€ ogren's syndrome, RA, inflammatory myositis, and Behc ßet's disease, only patients with autoimmune diseases demonstrated a higher incidence of cancer than that in the control population. Patients with Behc ßet's disease, which is considered to be a member of the autoinflammatory disease family, had normal rates of cancer (19) . Thus, it might be inferred from the 2 studies that the mechanisms underlying inflammation in autoimmunity and autoinflammation may diverge in their effect on tumorigenesis.
FMF could influence tumorigenesis in several ways. One may be related to the MEVF mutation observed in most FMF patients. This mutation enhances the activity of pyrin, the protein encoded by the MEFV gene (26) , which is known to regulate inflammation. Although the exact function of pyrin is not completely understood, its mutant form is suspected to enhance inflammasome activity, a feature of FMF and other autoinflammatory diseases. The inflammasomes are known to up-regulate the proinflammatory cytokines interleukin-1b (IL-1b) and IL-18, and to regulate cell death and autophagy (27) . Thus, several cancers have been directly linked to inflammasome-mediated inflammation, and the blockade of IL-1b has been shown to inhibit tumor growth (28) . However, inflammasomes may possess anticancer activity, by which malignant precursor cells are eliminated through pyroptotic cell death (29, 30) . This is evidenced by studies of epithelial skin cancer cell lines, in which the inflammasome exhibited tumorsuppressor properties in keratinocytes (31) .
Another possible explanation for the decreased rate of malignancy in FMF may be related to continuous * Standardized incidence ratio (SIR) analysis could not be performed separately for Ashkenazi Jews because of the low number of patients (n = 172). 95% CI = 95% confidence interval. (32) (33) (34) (35) , and inhibit tumor progression in animal models (36, 37) . Moreover, colchicine was shown to significantly reduce cancer incidence in male patients with gout in a large Taiwanese cohort with a median follow-up of 12 years (38) . In another study, colchicine administered postoperatively as adjuvant therapy inhibited breast cancer recurrence (39) . Notably, other antimicrotubule agents, such as taxanes and vinca alkaloids, are used regularly for cancer treatment (40, 41) . FMF patients take nonsteroidal antiinflammatory drugs (NSAIDs), which are effective in treating attacks that present due to colchicine failure or nonadherence to the treatment regimen. Aspirin and other NSAIDs were recently shown to reduce cancer rates (42) (43) (44) . We also speculate that the reduced cancer risk in FMF patients may be due to an effect of the disease on lifestyle factors. Several studies have demonstrated lower rates of obesity (2) and smoking (45) in FMF patients than in the general population. Furthermore, FMF patients may self-impose dietary restrictions due to their disease, which might also reduce cancer risk. The exceptions to the major trend of cancer reduction in our cohort are the significantly higher incidences of multiple myeloma and in situ cervical cancer. These findings are generally unexplained. It is notable, however, that a higher rate of MEFV mutations was reported in multiple myeloma patients than in a healthy control group (46) . Approximately 60% of multiple myeloma patients in one study had 1 of 5 MEFV mutations (M694V, M680I, V726A, M694I, or E148Q) (47) . With regard to the higher incidence of cervical cancer in FMF patients, the significant results are due to a higher rate of in situ cervical cancer than expected. In light of the clinical characteristics of FMF, which include abdominal pain, the possibility of surveillance bias cannot be excluded, since women with abdominal pain may be more likely to undergo gynecologic examination. Furthermore, the possibility that the increased incidence of in situ cervical cancer may be due to reduced resistance to papilloma virus in FMF cannot be excluded.
Our study has several limitations. MEFV gene analysis in the FMF patients was not available; therefore, we could not study the possible association between different MEFV mutations and specific cancers. In addition, data on FMF severity, colchicine dosage, and compliance with colchicine treatment are missing, which precludes further analysis of the findings. Due to the retrospective study design, FMF cancer patient data may have been missed; however, this flaw is balanced by a similar limitation in the reference population. Moreover, as FMF patients tend to be under close medical observation, escape from cancer detection is expected to be lower among these patients than in the general population. Another limitation of this study is that information on cancer cases diagnosed before 1960, when the Israel National Cancer Registry was established, are lacking. This limitation, however, is unlikely to have affected our conclusions, since only 1.8% of the FMF patients in our cohort were older than 30 in 1960. Since the incidence of cancer in persons younger than 30 years of age is negligible (48), the effect on the total cancer incidence results is negligible. The potential differences in the diagnosis of FMF over the period of the study are a further limitation of this study. Nevertheless, the clinical characteristics of a large cohort of FMF patients from Tel Hashomer described in 1967 (49) are virtually the same as those described later and in this study, and were the basis for the diagnostic criteria reported by Livneh et al in 1997 (50) , which have served as the FMF diagnostic criteria since then. Finally, for some of the Jewish population, we used the patients' parents' country of birth as the equivalent for the purpose of ethnic subgrouping.
In summary, this study is the first to examine a large cohort of FMF patients for cancer incidence. Previous epidemiologic studies of cancer incidence have focused on patients with autoimmune diseases. Our study demonstrated that contrary to inflammatory autoimmune diseases, FMF is characterized by a significantly lower incidence of cancer than that in the general population. These findings may stem from the pathogenesis of FMF, which differs from that of autoimmune diseases, or from colchicine treatment, an antimitotic agent used to treat almost all FMF patients. More studies of patients with FMF, as well as of patients with other autoinflammatory diseases, are needed to determine the nature and the mechanism of the association with cancer. Such research may further contribute to our understanding of the relationship between inflammation and cancer. In addition, our findings support the investigation of the potential use of colchicine as an anticancer agent.
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